NewsSudeep Pharma Limited Submits Q4FY26 Compliance Certificate Under SEBI Depositories RegulationsSudeep Pharma Limited Submits Q4FY26 Compliance Certificate Under SEBI Depositories Regulations
Sudeep Pharma Limited filed its Q4FY26 compliance certificate under SEBI Regulation 74(5) on April 10, 2026, covering the quarter ended March 31, 2026. The certificate, issued by registrar MUFG Intime India Private Limited, confirmed no demat requests were processed as all company shares remain in electronic mode. Company Secretary Dimple Mehta submitted the documentation to NSE and BSE, ensuring continued regulatory compliance for the Gujarat-based pharmaceutical company.
*this image is generated using AI for illustrative purposes only.
Sudeep pharma Limited has filed its quarterly compliance certificate with stock exchanges for the quarter ended March 31, 2026, in accordance with SEBI (Depositories and Participants) Regulations, 2018. The pharmaceutical company submitted the mandatory documentation to both the National Stock Exchange and BSE Limited on April 10, 2026.
Regulatory Compliance Certificate
The certificate was issued under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 by the company's registrar and share transfer agent, MUFG Intime India Private Limited (formerly Link Intime India Private Limited). The compliance document covers the quarter ended March 31, 2026.
| Parameter: | Details |
|---|---|
| Filing Date: | April 10, 2026 |
| Quarter Covered: | Q4FY26 (ended March 31, 2026) |
| Registrar: | MUFG Intime India Private Limited |
| Regulation: | SEBI Regulation 74(5) |
Share Transfer Agent Confirmation
MUFG Intime India Private Limited, serving as the registrar and share transfer agent, confirmed in their certificate that no demat requests were received for processing during the quarter ended March 31, 2026. The registrar stated that all shares of Sudeep Pharma Limited are held in electronic mode only, eliminating the need for any dematerialization processing.
The confirmation was signed by Damodar Kambli, Assistant Vice President at MUFG Intime India Private Limited, and bears reference number CSC/SUDEEP/2026. MUFG Intime India Private Limited operates from their registered address at C-101, Embassy 247, L.B.S. Marg, Vikhroli (West), Mumbai.
Company Secretary Filing
Company Secretary and Compliance Officer Dimple Mehta (Membership No. F13184) digitally signed and submitted the compliance certificate to both stock exchanges. The filing ensures the company meets its regulatory obligations under SEBI depositories regulations.
| Exchange: | Trading Symbol/Code |
|---|---|
| National Stock Exchange: | SUDEEP PHRM |
| BSE Limited: | 544619 |
The pharmaceutical company, headquartered at 129/1/A, G.I.D.C. Estate, Nandesari, Vadodara, Gujarat, continues to maintain full compliance with SEBI regulations regarding depositories and participant requirements. The quarterly certificate submission represents standard regulatory practice for listed companies to confirm the status of their share dematerialization processes.
Historical Stock Returns for Sudeep Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.56% | -0.85% | +9.33% | -21.22% | -21.22% | -21.22% |
What are Sudeep Pharma's growth prospects and pipeline developments that could drive investor interest in Q1FY27?
How might the recent rebranding of Link Intime to MUFG Intime impact registrar services for mid-cap pharmaceutical companies?
Will Sudeep Pharma consider any corporate actions or capital restructuring initiatives in the upcoming financial year?
18
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
